Clinical Trial Update: Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer [Phase 2, Phase 3]

View source ↗

Summary

NRG Oncology reports suspension of a phase 2/3 trial comparing cisplatin dosing every three weeks versus weekly when given with radiation for advanced head and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cutaneous Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Hpv-negative Oropharyngeal Squamous Cell Carcinoma
• Hpv-positive Oropharyngeal Squamous Cell Carcinoma
• Hypopharyngeal Squamous Cell Carcinoma
• Laryngeal Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)

Snippet

Sponsor: NRG Oncology | Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 2, Phase 3 | Status: SUSPENDED